Physician profile
Jessica E Eide
NPI 1912242330
$756.92
in general payments reported to CMS, 2019-2025
11 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $199 · 2022: $139 · 2023: $172 · 2024: $124 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $418.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $239.04 | 2021-2025 | Fasenra, Tezspire, Imfinzi |
| Glaxosmithkline, LLC. | $148.27 | 2021-2023 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $122.69 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $73.15 | 2022-2024 | Dupixent |
| United Therapeutics Corporation | $32.23 | 2025 | Tyvaso |
| Mylan Specialty L.P. | $28.86 | 2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $27.59 | 2025 | |
| Liquidia Technologies, INC. | $23.44 | 2025 | Yutrepia |
| Pfizer INC. | $21.59 | 2024 | |
| Grifols USA, LLC | $20.14 | 2023 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Eide listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.